Merck's innovative oncology pipeline of dna damage response inhibitors and antibody-drug conjugates poised to advance cancer treatment

Darmstadt, germany--(business wire)--merck, a leading science and technology company, today shared updates on the company's oncology pipeline and focused approach to the research and development of potential new medicines designed to improve the futures of people with cancer. this year, the company plans to open multiple new phase ib and ii clinical studies for tuvusertib and m9466, key assets from its broad portfolio of dna damage response (ddr) inhibitors; has advanced its lead antibody-drug.
DNA Ratings Summary
DNA Quant Ranking